Personalized Immunosuppression in Transplantation Role of Biomarker Monitoring and Therapeutic Drug Monitoring

Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring is a comprehensive and clinically focused reference that explores the evolving strategies for optimizing immunosuppressant therapy in organ transplant recipients. This volume integrates traditional therapeutic drug monitoring (TDM) with cutting-edge approaches such as biomarker-guided therapy and pharmacogenomics, helping clinicians tailor immunosuppression regimens to individual patients for improved outcomes and reduced toxicity.

Written by experts in pathology, clinical pharmacology, toxicology, and transplant medicine, this book offers both the scientific foundation and practical guidelines necessary for precise management of immunosuppressants. It serves as a critical tool for clinicians seeking to personalize treatment protocols in kidney, liver, heart, and other solid organ transplantation, reducing the risk of rejection while minimizing adverse drug reactions.

Key Features:

• Integrated Approach to Monitoring: Combines traditional therapeutic drug monitoring with emerging biomarker strategies and pharmacogenomic profiling to guide individualized therapy.

• Clinical Practicality: Offers detailed, evidence-based guidelines for therapeutic ranges, dosing adjustments, monitoring frequency, and interpreting lab results across various immunosuppressants (e.g., tacrolimus, cyclosporine, sirolimus, mycophenolate).

• Biomarker Applications: Explains when and how to use immune function biomarkers (e.g., cytokine levels, donor-derived cell-free DNA, gene expression assays) to detect early rejection or over-immunosuppression.

• Pharmacogenomics in Practice: Provides guidance on incorporating genetic testing (e.g., CYP3A5, TPMT, UGT1A9 polymorphisms) to inform drug metabolism and personalize dosing.

• Methodological Insights: Reviews the analytical techniques used to measure drug concentrations in whole blood and plasma, highlighting common pitfalls, inter-laboratory variability, and quality control issues.

• Target Audience: Tailored for pathologists, clinical toxicologists, transplant surgeons, nephrologists, hepatologists, and pharmacologists involved in transplant care and drug monitoring.

• Clinical Case Examples: Includes real-world case studies and clinical scenarios that illustrate how personalized immunosuppression strategies are applied in practice.

• Regulatory and Safety Considerations: Discusses regulatory aspects of biomarker use and TDM, along with risk mitigation strategies for adverse effects and immunosuppression-related complications.